Koutarou Iemitsu

Learn More
BACKGROUND Sitagliptin is a DPP-4 inhibitor that became available for use in Japan three years ago. This study was conducted to identify the pleiotropic effects of sitagliptin other than blood glucose lowering in Japanese type 2 diabetes mellitus patients. METHODS A retrospective, observational study of 940 type 2 diabetes mellitus patients was conducted.(More)
  • 1